Please login to the form below
Alkermes
This page shows the latest Alkermes news and features for those working in and with pharma, biotech and healthcare.
Alkermes’ new antipsychotic clears FDA advisory committee hurdle
Alkermes’ experimental antipsychotic for schizophrenia and bipolar I disorder ALKS 3831 has cleared an US Food and Drug Administration (FDA) expert advisory committee review. ... and bipolar I disorder,” said Craig Hopkinson, chief medical officer
Latest news
-
Troubled Alkermes eyes November OK for new antipsychotic
Review begins for potential schizophrenia and bipolar I disorder drug. The FDA has started its review of Alkermes’ experimental antipsychotic for schizophrenia and bipolar I disorder – ALKS 3831 – setting up a ... That left Alkermes more reliant on
-
Alkermes boosts CNS presence with $950m Rodin acquisition
Much now rests on the Rodin deal, with Alkermes likely hoping it can expand its portfolio significantly with promising new growth products. ... to us as we have advanced our internal pipeline of medicines for CNS disorders,” said Richard Pops, chief
-
Biogen under fire over $88,000 Vumerity annual price
Biogen and partner Alkermes scored FDA approval for Vumerity (diroximel fumarate) on the 30 October for the treatment of relapsing forms of MS.
-
Tecfidera successor’s side-effect profile boosts Biogen
Vumerity is being developed by Biogen in partnership with Alkermes, and is already filed with the FDA, with a decision due in Q4 of 2019.
-
Biogen trumpets safety data for Tecfidera follow-up
Alkermes-partnered diroximel fumarate (formerly BIIB098) – which has the proposed trade name Vumerity – is due for an FDA verdict before the end of the year, mere months before Biogen is due
More from news
Approximately 8 fully matching, plus 33 partially matching documents found.
Latest Intelligence
-
Medius Deal Watch table for March 2015
205. Alkermes / Recro. Asset acquisition. Purchase of US factory and associated products and pipeline.
-
Pharma deals in March 2015
0.3. 18. 108%. SuppreMol. Baxter. 0.2. No sales. NA. Alkermes (asset).
-
Going the distance
The companies have already succeeded where ill-fated programmes from Lilly/Alkermes and Novo Nordisk/Aradigm failed, but it must now prove it can do better than Pfizer's Exubera, launched
-
Pharma deals during September 2014
2011. Alkermes. Elan. Ireland. 2012. Jazz. Azur. Ireland. 2013. Liberty Global.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Srdjan Stankovic joins Acadia Pharmaceuticals
He moves to the San Diego biopharma from Alkermes. San Diego biopharmaceutical company Acadia Pharmaceuticals has appointed Srdjan (Serge) Stankovic as executive vice president, head of research and development. ... He joins the firm from Alkermes,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- LEO Pharma enters clinical trial partnership with ICON
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- The Considered appoints Bam Zahraie as chief experience officer
- The impact of pharma congresses on HCPs – virtual and in person
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- A relentless commitment to neuroscience
- Putting the ovation into innovation: trends from ESMO
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Sanofi to acquire Provention Bio in deal worth $2.9bn
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
